ArticleJournal of asthma and allergy2026
A Pilot Study on Early-Phase Efficacy and Biomarker Analysis of Cervical Intralymphatic Immunotherapy for Seasonal Rhinoconjunctivitis.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Seasonal allergic rhinitis (SAR) imposes substantial morbidity, and intralymphatic immunotherapy (ILIT) offers a targeted approach for allergen delivery. However, short-term efficacy and associated biomarkers remain insufficiently characterized. Methods: Eight SAR patients received ultrasound-guided ILIT with 100 SQ-U allergen extracts injected into cervical lymph nodes. Assessments were performed at baseline, 1 month, and 2 months post-treatment, alongside eight age- and gender-matched healthy controls. Symptom severity was evaluated using Visual Analog Scale (VAS) and Combined Symptom and Medication Scores (CSMSs). Transcriptomic analysis of peripheral blood mononuclear cells (PBMCs) identified differentially expressed genes (DEGs), followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Serum levels of specific and total IgE, together with 96 inflammatory proteins, were also quantified. Results: ILIT was associated with significant reductions in VAS and CSMSs at one month, with sustained improvement at two months during peak pollen season. Transcriptomic analysis identified 525 DEGs (p ≤ 0.05), reflecting a shift from Th2-dominant response toward Th1 and regulatory T-cell (Treg) phenotypes. Key genes included transcriptional regulator CREM, cytokine IFNG, signaling component TNFAIP3, and chemotaxis-related molecules (CXCR5, CCR4, CCR6, TNFSF14, CCL20), identifying a candidate multi-gene profile of early ILIT response. Serum proteomic analysis showed downregulated CCL20 and upregulated TNFRSF9, though these protein changes correlated weakly with tissue mRNA expression and showed limited between-group variation, indicating insufficient sensitivity for diagnostic or efficacy assessment. Conclusion: ILIT achieves rapid symptom relief in SAR, with transcriptomic and proteomic evidence of immune tolerance induction and innate immune activation. These biomarkers may support early efficacy monitoring, warranting confirmation in larger trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.